CO2024000096A2 - Nuevos compuestos selectivos de angiotensina ii - Google Patents
Nuevos compuestos selectivos de angiotensina iiInfo
- Publication number
- CO2024000096A2 CO2024000096A2 CONC2024/0000096A CO2024000096A CO2024000096A2 CO 2024000096 A2 CO2024000096 A2 CO 2024000096A2 CO 2024000096 A CO2024000096 A CO 2024000096A CO 2024000096 A2 CO2024000096 A2 CO 2024000096A2
- Authority
- CO
- Colombia
- Prior art keywords
- selective compounds
- new angiotensin
- compounds
- angiotensin
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2109946.0A GB202109946D0 (en) | 2021-07-09 | 2021-07-09 | New compounds |
| GBGB2202664.5A GB202202664D0 (en) | 2022-02-25 | 2022-02-25 | New compounds |
| PCT/GB2022/051760 WO2023281271A1 (en) | 2021-07-09 | 2022-07-08 | New selective angiotensin ii compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024000096A2 true CO2024000096A2 (es) | 2024-05-10 |
Family
ID=82608432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000096A CO2024000096A2 (es) | 2021-07-09 | 2024-01-09 | Nuevos compuestos selectivos de angiotensina ii |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240262813A1 (enExample) |
| EP (1) | EP4367110A1 (enExample) |
| JP (1) | JP2024523576A (enExample) |
| KR (1) | KR20240035402A (enExample) |
| AU (1) | AU2022306778A1 (enExample) |
| CA (1) | CA3222721A1 (enExample) |
| CL (1) | CL2024000066A1 (enExample) |
| CO (1) | CO2024000096A2 (enExample) |
| IL (1) | IL309605A (enExample) |
| MX (1) | MX2024000518A (enExample) |
| WO (1) | WO2023281271A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3222721A1 (en) | 2021-07-09 | 2023-01-12 | Nadia Nasser PETERSEN | New selective angiotensin ii compounds |
| CN120569378A (zh) * | 2023-01-09 | 2025-08-29 | 维科尔药物公司 | 选择性血管紧张素ii化合物 |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464853A (en) | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5198438A (en) | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| NZ306734A (enExample) | 1995-04-04 | 2000-01-28 | Texas Biotechnology Corp | |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| PT1094816E (pt) * | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
| JP4707321B2 (ja) * | 2001-05-31 | 2011-06-22 | ヴィコール・ファルマ・アーベー | アンギオテンシンｉｉアゴニストとして有用な三環式化合物 |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| BRPI0708507A2 (pt) * | 2006-03-03 | 2011-05-31 | Torrent Pharmaceuticals Ltd | Novos antagonistas de receptores de dupla ação (dara) para os receptores at1 eta |
| US8835471B2 (en) * | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| SG11201704473WA (en) | 2014-12-12 | 2017-06-29 | Vicore Pharma Ab | New methods and uses |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| AU2016227486A1 (en) | 2015-03-02 | 2017-08-17 | Vicore Pharma Ab | Angiotensin ll receptor agonist for treating pulmonary fibrosis |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| PH12022552413A1 (en) * | 2020-03-19 | 2024-01-08 | Vicore Pharma Ab | Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii |
| CA3222721A1 (en) | 2021-07-09 | 2023-01-12 | Nadia Nasser PETERSEN | New selective angiotensin ii compounds |
-
2022
- 2022-07-08 CA CA3222721A patent/CA3222721A1/en active Pending
- 2022-07-08 EP EP22743876.9A patent/EP4367110A1/en active Pending
- 2022-07-08 US US18/577,856 patent/US20240262813A1/en active Pending
- 2022-07-08 AU AU2022306778A patent/AU2022306778A1/en active Pending
- 2022-07-08 MX MX2024000518A patent/MX2024000518A/es unknown
- 2022-07-08 JP JP2023579654A patent/JP2024523576A/ja active Pending
- 2022-07-08 IL IL309605A patent/IL309605A/en unknown
- 2022-07-08 KR KR1020237044464A patent/KR20240035402A/ko active Pending
- 2022-07-08 WO PCT/GB2022/051760 patent/WO2023281271A1/en not_active Ceased
-
2024
- 2024-01-08 CL CL2024000066A patent/CL2024000066A1/es unknown
- 2024-01-09 CO CONC2024/0000096A patent/CO2024000096A2/es unknown
- 2024-12-10 US US18/975,881 patent/US12441718B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12441718B2 (en) | 2025-10-14 |
| CA3222721A1 (en) | 2023-01-12 |
| CL2024000066A1 (es) | 2024-06-28 |
| IL309605A (en) | 2024-02-01 |
| KR20240035402A (ko) | 2024-03-15 |
| US20250101010A1 (en) | 2025-03-27 |
| AU2022306778A1 (en) | 2024-01-18 |
| MX2024000518A (es) | 2024-01-31 |
| WO2023281271A1 (en) | 2023-01-12 |
| US20240262813A1 (en) | 2024-08-08 |
| EP4367110A1 (en) | 2024-05-15 |
| JP2024523576A (ja) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022003091A2 (es) | Nuevos compuestos | |
| CO2023002347A2 (es) | Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii | |
| CY1119530T1 (el) | Συνθεσεις και μεθοδοι ρυθμισης toy fxr | |
| PH12020500257A1 (en) | Quinoline derivatives for treating infections with helminths | |
| MY196327A (en) | New Anthelmintic Quinoline-3-Carboxamide Derivative | |
| MX2023001647A (es) | Sulfonilureas y compuestos relacionados y uso de estos. | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| EA200802203A1 (ru) | Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов | |
| PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| TN2012000417A1 (en) | Compounds as bradykinin b1 antagonists | |
| PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
| CR20180541A (es) | Inhibidores de bromodominios | |
| PH12017502201A1 (en) | Substituted pyridines and method of use | |
| MX391489B (es) | Inhibidores heterociclicos de mct4. | |
| PH12021553074A1 (en) | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| PH12019502365A1 (en) | New bicyclic pyrazole derivatives | |
| PH12018501575A1 (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| MX2024000518A (es) | Nuevos compuestos selectivos de angiotensina ii. | |
| MX2012009224A (es) | Compuestos en calidad de antagonistas de bradiquinina-b1. | |
| PE20151062A1 (es) | PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO | |
| MX2019011545A (es) | Composiciones celulares y de andamio inyectables. | |
| PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| PE20161070A1 (es) | N-aril piridinonas sustituidas |